Evidence, politics, and technological change

Health Affairs

Volumn 24, Issue 1, 2005, Pages 29-40

  Gelijns, Annetine C ^a,b,c   Brown, Lawrence D ^a,b,c   Magnell, Corey ^a,b   Ronchi, Elettra ^a,b,c   Moskowitz, Alan J ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b OECD   (France)

^c Dept Surg Sci Hlth Plcy Mgmt ^*

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; POLITICS; REVIEW; TECHNOLOGY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; EVIDENCE-BASED MEDICINE; HUMANS; POLITICS; PUBLIC POLICY; TECHNOLOGY, MEDICAL;

EID: 12944289489     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.1.29     Document Type: Review

References (21)

1. J.E. Wennberg, B.A. Barnes, and M. Zubkoff, "Professional Uncertainty and the Problem of Supplier-induced Demand," Social Science and Medicine 16, no. 7 (1982): 811-824.
2. U.S. Food and Drug Administration, CDER 2002 Report to the Nation: Improving Public Health through Human Drugs (Washington: FDA, 13 May 2003); and FDA, Office of Device Evaluation Annual Report, Fiscal Year 2002 (Washington: FDA, 4 December 2002).
3. U.S. Food and Drug Administration, CDER 2002 Report to the Nation: Improving Public Health through Human Drugs (Washington: FDA, 13 May 2003); and FDA, Office of Device Evaluation Annual Report, Fiscal Year 2002 (Washington: FDA, 4 December 2002).
4. M. Hlatky et al., "Tying Clinical Research to Patient Care by Use of an Observational Database," Statistics in Medicine 3 (1984): 375-384.
5. A. Gelijns and N. Rosenberg, "The Dynamics of Technological Change in Medicine," Health Affairs 13, no. 3 (1994): 28-46.
6. A.C. Gelijns, N. Rosenberg, and A.J. Moskowitz, "Capturing the Unexpected Benefits of Medical Research," New England Journal of Medicine 339, no. 10 (1998): 693-698.
7. I b i d.
8. A.A. Stinnett and J. Mullahy, "Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis," Medical Decision Making 18, no. 2 (Supp.) (1998): S68-S80; and D.F. Heitjan, A.J. Moskowitz, and W. Whang, "Problems with Interval Estimates of the Incremental Cost-Effectiveness Ratio," Medical Decision Making 19, no. 9 (1999): 9-15.
9. A.A. Stinnett and J. Mullahy, "Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis," Medical Decision Making 18, no. 2 (Supp.) (1998): S68-S80; and D.F. Heitjan, A.J. Moskowitz, and W. Whang, "Problems with Interval Estimates of the Incremental Cost-Effectiveness Ratio," Medical Decision Making 19, no. 9 (1999): 9-15.
10. A.M. Garber and C.E. Phelps, "Economic Foundations of Cost-Effectiveness Analysis," Journal of Health Economics 16, no. 1 (1997): 1-31.
11. S.R. Tunis, D.B. Stryer, and C.M. Clancy, "Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy," Journal of the American Medical Association 290, no. 12 (2003): 1624-1632.
12. D.P. Carpenter, "The Political Economy of FDA Drug Review: Processing, Politics, and Lessons for Policy," Health Affairs 23, no. 1 (2004): 52-63.
13. Institute of Medicine, Biomedical Politics (Washington: National Academies Press, 1991).
14. T. Rector, J. Cohn, and Pimobendan Multicenter Research Group, "Assessment of Patient Outcome with the Minnesota Living with Heart Failure Questionnaire: Reliability and Validity during a Randomized, Double-Blind, Controlled Trial of Pimodbendan," American Heart Journal 124, no. 4 (1992): 1017-1025.
15. R. Steinbrook, "Waiting for Plan B - the FDA and Nonprescription Use of Emergency Contraception," New England Journal of Medicine 350, no. 23 (2004): 2327-2329; and J.M. Drazen, "Legislative Myopia on Stem Cells," New England Journal of Medicine 349, no. 3 (2003): 300.
16. R. Steinbrook, "Waiting for Plan B - the FDA and Nonprescription Use of Emergency Contraception," New England Journal of Medicine 350, no. 23 (2004): 2327-2329; and J.M. Drazen, "Legislative Myopia on Stem Cells," New England Journal of Medicine 349, no. 3 (2003): 300.
17. A. Williams, "Priority Setting in a Needs-based System," in Medical Innovation at the Crossroads, Volume 3: Technology and Health Care in an Era of Limits, ed. A.C. Gelijns (Washington: National Academies Press, 1992).
18. E. Rose et al., "Long-Term Mechanical Left Ventricular Assistance for End Stage Heart Failure," New England Journal of Medicine 345, no. 20 (2001): 1435-1443.
19. BlueCross BlueShield Association Technology Evaluation Center, "Special Report: Cost-Effectiveness of Left-Ventricular Assist Devices as Destination Therapy for End-Stage Heart Failure," Chicago TEC Assessment Program 19, no. 2 (2004): 1-35.
20. Ministry of Health, Welfare, and Cultural Affairs, Making Choices in Health Care (Rijswijk, Netherlands: Ministry of Health, Welfare, and Cultural Affairs, 1991).
21. K. Syrett, "A Technocratic Fix to the 'Legitimacy Problem'? The Blair Government and Health Care Rationing in the United Kingdom," Journal of Health Politics, Policy and Law 28, no. 4 (2003): 715-746.